Literature DB >> 12880296

Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride.

C G Thanos1, Z Liu, J Reineke, E Edwards, E Mathiowitz.   

Abstract

PURPOSE: This study was carried out to show the effect of particle size reduction and bioadhesion on the dissolution and relative bioavailability of dicumarol.
METHODS: Formulations were produced by a variety of methods including a novel technique to reduce particle size as well as phase inversion with poly(fumaric-co-sebacic)anhydride p(FA:SA) to create nanospheres. Drug was administered to groups of pigs and rats via oral gavage of a suspension, and dicumarol concentration in the blood was measured using a double extraction technique.
RESULTS: In vitro results showed improved dissolution in both the micronized formulation and the encapsulated p(FA:SA) nanospheres. In vivo, relative bioavailability of a spray-dried formulation was increased by 17% in the rat and 72% in the pig by further reduction in particle size. The bioadhesive p(FA:SA) formulation also improved relative bioavailability over the spray-dried drug, increasing it by 55% in the rat and 96% in the pig. Additionally, the p(FA:SA) formulation prolonged Tmax and decreased Cmax in both species.
CONCLUSION: This work demonstrates the importance of particle size and bioadhesion to improve oral bioavailability of ducumarol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880296     DOI: 10.1023/a:1024474609667

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Nanosuspensions of poorly soluble drugs--reproducibility of small scale production.

Authors:  M J Grau; O Kayser; R H Müller
Journal:  Int J Pharm       Date:  2000-03-10       Impact factor: 5.875

Review 2.  Characteristics and significance of the amorphous state in pharmaceutical systems.

Authors:  B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1997-01       Impact factor: 3.534

3.  Studies on drug-milk freeze-dried formulations. I: Bioavailability of sulfamethizole and dicumarol formulations.

Authors:  P E Macheras; C I Reppas
Journal:  J Pharm Sci       Date:  1986-07       Impact factor: 3.534

4.  Comparative pharmacokinetics of coumarin anticoagulants. I. Unusual interaction of bishydroxycoumarin with plasma proteins--development of a new assay.

Authors:  R Nagashima; G Levy; E Nelson
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

Review 5.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

6.  Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. IV. Chloramphenicol--urea system.

Authors:  A H Goldberg; M Gibaldi; J L Kanig; M Mayersohn
Journal:  J Pharm Sci       Date:  1966-06       Impact factor: 3.534

7.  The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment.

Authors:  S M Khoo; C J Porter; W N Charman
Journal:  Int J Pharm       Date:  2000-09-15       Impact factor: 5.875

8.  Poly(fumaric-co-sebacic anhydride). A degradation study as evaluated by FTIR, DSC, GPC and X-ray diffraction.

Authors:  C A Santos; B D Freedman; K J Leach; D L Press; M Scarpulla; E Mathiowitz
Journal:  J Control Release       Date:  1999-06-28       Impact factor: 9.776

9.  Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres.

Authors:  E J Lee; S W Lee; H G Choi; C K Kim
Journal:  Int J Pharm       Date:  2001-05-07       Impact factor: 5.875

10.  Poly(fumaric-co-sebacic) microspheres as oral drug delivery systems.

Authors:  D Chickering; J Jacob; E Mathiowitz
Journal:  Biotechnol Bioeng       Date:  1996-10-05       Impact factor: 4.530

View more
  5 in total

1.  Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin.

Authors:  Malgorzata S Cartiera; Elisa C Ferreira; Christina Caputo; Marie E Egan; Michael J Caplan; W Mark Saltzman
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

2.  Biocoating-A Critical Step Governing the Oral Delivery of Polymeric Nanoparticles.

Authors:  Aharon Azagury; Cameron Baptista; Kosta Milovanovic; Hyeseon Shin; Peter Morello; James Perez-Rogers; Victoria Goldenshtein; Travis Nguyen; Arianna Markel; Soham Rege; Stephanie Hojsak; Alexander Perl; Carder Jones; Megan Fife; Stacia Furtado; Edith Mathiowitz
Journal:  Small       Date:  2022-05-23       Impact factor: 15.153

3.  Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres.

Authors:  Joshua J Reineke; Daniel Y Cho; Yu-Ting Dingle; A Peter Morello; Jules Jacob; Christopher G Thanos; Edith Mathiowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-06       Impact factor: 11.205

4.  Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery.

Authors:  Ndidi C Ngwuluka; Viness Pillay; Yahya E Choonara; Girish Modi; Dinesh Naidoo; Lisa C du Toit; Pradeep Kumar; Valence M K Ndesendo; Riaz A Khan
Journal:  Int J Mol Sci       Date:  2011-09-23       Impact factor: 5.923

5.  Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity.

Authors:  Hongxing Wang; Qigui Li; Sean Reyes; Jing Zhang; Lisa Xie; Victor Melendez; Mark Hickman; Michael P Kozar
Journal:  Malar Res Treat       Date:  2013-05-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.